ProQR Therapeutics (NASDAQ: PRQR) is a biotechnology company based in the Netherlands that's currently developing RNA therapies for rare genetic diseases. ProQR is at the moment investigating two treatments for a rare genetic disease called Usher syndrome, QR-421a and QR-411. Though the latter is still in preclinical studies, recent phase 1/2 trial results from the STELLAR trial for QR-421a are promising. When that data was released March 24, ProQR's stock increased from $5.68 to $9.22. As of 10 a.m. April 4, the stock price is currently at $6.50.
Could these favorable results mean good things for investors? Let's look into the company and find out.
For further details see:
An End to This Rare Syndrome Could Be an Opportunity for Investors